is 510(k) cleared and CE marked. Prosigna is available to healthcare professionals in the United States, in markets that recognize the CE mark, and/or in which Prosigna is registered.
Recognized as one of
Top 10 Innovations of 2013
This site is intended for US residents only.
Download the updated Prosigna Package Insert and nCounter Dx User Manual:
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From ABCSG-8 (
NanoString launches Prosigna Patient Support to help patients gain access to Prosigna.
Download the enrollment form today
Analytical validation study shows precision and reproducibility of PAM50-based Prosigna (
Study confirms ability of the Prosigna assay to assess risk of late distant recurrence
ABCSG-8 Clinical Validation Study (
Top Ten Innovations of 2013
Prognostic factors in late recurrence (
TransATAC Clinical Validation Study (
Managing patients with
early-stage breast cancer…
…begins with a highly
accurate assessment of risk
Mastering the science
of tumor biology
uses the PAM50 gene
signature to translate tumor
biology into your patient's individualized
Learn about PAM50 >
Advanced technology generates precise,
reproducible prognostic information in
local qualified laboratories.
you can trust
your patient's 10-year risk
of distant recurrence.
Clinical validation data >
© 2015 NanoString Technologies, Inc. All rights reserved. NanoString, the NanoString Technologies logo, nCounter, Prosigna and the Prosigna logo are trademarks and/or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Terms of Sale
back to top